- Home
- VYGR vs DYNX Comparison
VYGR vs DYNX Comparison
Compare VYGR & DYNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- DYNX
- Stock Information
- Founded
- VYGR 2013
- DYNX 2024
- Country
- VYGR United States
- DYNX United States
- Employees
- VYGR N/A
- DYNX N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- DYNX
- Sector
- VYGR Health Care
- DYNX
- Exchange
- VYGR Nasdaq
- DYNX NYSE
- Market Cap
- VYGR 222.9M
- DYNX 220.4M
- IPO Year
- VYGR 2015
- DYNX 2024
- Fundamental
- Price
- VYGR $3.16
- DYNX $9.95
- Analyst Decision
- VYGR Strong Buy
- DYNX
- Analyst Count
- VYGR 9
- DYNX 0
- Target Price
- VYGR $14.86
- DYNX N/A
- AVG Volume (30 Days)
- VYGR 396.9K
- DYNX 46.0K
- Earning Date
- VYGR 05-12-2025
- DYNX 01-01-0001
- Dividend Yield
- VYGR N/A
- DYNX N/A
- EPS Growth
- VYGR N/A
- DYNX N/A
- EPS
- VYGR N/A
- DYNX N/A
- Revenue
- VYGR $80,001,000.00
- DYNX N/A
- Revenue This Year
- VYGR N/A
- DYNX N/A
- Revenue Next Year
- VYGR $2.04
- DYNX N/A
- P/E Ratio
- VYGR N/A
- DYNX N/A
- Revenue Growth
- VYGR N/A
- DYNX N/A
- 52 Week Low
- VYGR $2.75
- DYNX $9.78
- 52 Week High
- VYGR $9.55
- DYNX $10.48
- Technical
- Relative Strength Index (RSI)
- VYGR 38.34
- DYNX N/A
- Support Level
- VYGR $2.75
- DYNX N/A
- Resistance Level
- VYGR $3.34
- DYNX N/A
- Average True Range (ATR)
- VYGR 0.26
- DYNX 0.00
- MACD
- VYGR 0.03
- DYNX 0.00
- Stochastic Oscillator
- VYGR 41.41
- DYNX 0.00
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About DYNX DYNAMIX CORP
Dynamix Corp is a blank check company.